Reviewer’s report

**Title:** Multimodal therapy for synergic inhibition of tumour cell invasion and tumour-induced angiogenesis

**Version:** 3  **Date:** 9 February 2010

**Reviewer:** Jasti Rao

**Reviewer’s report:**

Major Compulsory Revisions.

This revised manuscript entitled "Multimodal therapy for synergic inhibition of tumour cell invasion and tumour-induced angiogenesis" by Zengel et al demonstrated that combination of three inhibitors (WX-UK1, galardin, COX-2) inhibited invasion, migration and angiogenesis. The authors responded to a few of the reviewers’ concerns, but there are still several concerns regarding this revised manuscript.

1. How did these inhibitors have no effect on invasion of these cells (galardin and celecoxib)? The authors’ response to this concern was not satisfied. How does this concentration inhibit bFGF, etc?

2. No data showing that these compounds had any effect on the levels of COX2, MMP-1, MMP-2, MMP-3, MMP-9, VEGF and uPA, etc.

3. How did triple combination have more effect on HeLa cells than FaDu, where single concentration of these drugs had more effect on the invasive behavior of FaDu cells compared to HeLA cells?

4. How did COX1 have more effect than triple combination on the levels of bFGF in FaDu cells?

5. Why did they not perform the effect of Cox1 in angiogenic assay compared to triple combination effect?

6. Finally, as mentioned earlier, the in vivo studies are more important in order to consider these studies novel.

**Level of interest:** An article of limited interest

**Quality of written English:** Acceptable

**Statistical review:** Yes, and I have assessed the statistics in my report.

**Declaration of competing interests:**

I declare I have no competing interests.